Insightec touts 1st patient treated in Exablate Neuro FDA feasibility trial

Insightec today announced that the 1st patient has been treated in a feasibility trial exploring the use of its Exablate Neuro system for treating benign centrally-located intracranial tumors in pediatric and young adults. The Exablate Neuro device uses high-intensity, focused ultrasound to thermally ablate targeted tissue, guided by continuous magnetic resonance imaging; the procedure can be performed non-invasively through an intact skull. A team at the Nicklaus Children’s Hospital performed the 1st procedure on a 21-year old patient suffering from seizures associated with a benign hypothalamic hamartoma brain tumor. “This breakthrough first procedure sets the stage for us to provide incisionless surgery for young patients with benign centrally-located brain tumors. Our team is encouraged by the potential of focused ultrasound technology to positively impact lives,” Dr. Prasanna Jayakar of the Brain Institute at Nicklaus Children’s Hospital said in a prepared statement. “We applaud the team at Nicklaus Children’s for their commitment to treating children with various brain conditions. Their pioneering research with our MRgFUS technology offers hope that significant groups of pediatric patients will be able to undergo treatment without any surgical incision, minimizing or eliminating the risk of infection or other surgical complications,” Insightec chair & CEO Dr. Maurice Ferré said in prepared remarks. “The needs of pe...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Neurological InSightec Ltd Source Type: news